BRAIN Biotech AG (BNN) - Total Assets
Based on the latest financial reports, BRAIN Biotech AG (BNN) holds total assets worth €66.34 Million EUR (≈ $77.55 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check BNN cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
BRAIN Biotech AG - Total Assets Trend (2012–2025)
This chart illustrates how BRAIN Biotech AG's total assets have evolved over time, based on quarterly financial data. Explore BNN long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
BRAIN Biotech AG - Asset Composition Analysis
Current Asset Composition (September 2025)
BRAIN Biotech AG's total assets of €66.34 Million consist of 37.6% current assets and 62.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €6.19 Million | 9.3% |
| Accounts Receivable | €9.00 Million | 13.6% |
| Inventory | €8.94 Million | 13.5% |
| Property, Plant & Equipment | €27.55 Million | 41.5% |
| Intangible Assets | €5.87 Million | 8.8% |
| Goodwill | €6.63 Million | 10.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how BRAIN Biotech AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BRAIN Biotech AG stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BRAIN Biotech AG's current assets represent 37.6% of total assets in 2025, a decrease from 53.5% in 2012.
- Cash Position: Cash and equivalents constituted 9.3% of total assets in 2025, down from 12.9% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 10.0% in 2012.
- Asset Diversification: The largest asset category is property, plant & equipment at 41.5% of total assets.
BRAIN Biotech AG Competitors by Total Assets
Key competitors of BRAIN Biotech AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Akzo Nobel NV
AS:AKZA
|
Netherlands | €13.95 Billion |
|
Air Products and Chemicals Inc
NYSE:APD
|
USA | $41.24 Billion |
|
AKZO NOBEL SPONS.ADRS 1/3
F:AKUP
|
Germany | €15.49 Billion |
|
SKC Co. Ltd
KO:011790
|
Korea | ₩6.77 Trillion |
|
Shandong Dongyue Organosilicon Mat
SHE:300821
|
China | CN¥6.27 Billion |
|
Ningbo Shanshan Co Ltd
SHG:600884
|
China | CN¥45.88 Billion |
|
Jiangsu Ruitai New Energy Materials Co. Ltd.
SHE:301238
|
China | CN¥9.46 Billion |
|
5N Plus Inc.
TO:VNP
|
Canada | CA$519.27 Million |
BRAIN Biotech AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.42 | 1.83 | 2.70 |
| Quick Ratio | 0.91 | 1.45 | 2.70 |
| Cash Ratio | 0.35 | 1.09 | 0.00 |
| Working Capital | €7.36 Million | €20.65 Million | €18.35 Million |
BRAIN Biotech AG - Advanced Valuation Insights
This section examines the relationship between BRAIN Biotech AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 26.70 |
| Latest Market Cap to Assets Ratio | 0.78 |
| Asset Growth Rate (YoY) | -25.2% |
| Total Assets | €66.34 Million |
| Market Capitalization | $51.56 Million USD |
Valuation Analysis
Below Book Valuation: The market values BRAIN Biotech AG's assets below their book value (0.78x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: BRAIN Biotech AG's assets decreased by 25.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BRAIN Biotech AG (2012–2025)
The table below shows the annual total assets of BRAIN Biotech AG from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | €66.34 Million ≈ $77.55 Million |
-25.24% |
| 2024-09-30 | €88.74 Million ≈ $103.74 Million |
+25.09% |
| 2023-09-30 | €70.94 Million ≈ $82.93 Million |
-9.05% |
| 2022-09-30 | €77.99 Million ≈ $91.18 Million |
+0.33% |
| 2021-09-30 | €77.74 Million ≈ $90.88 Million |
+7.74% |
| 2020-09-30 | €72.15 Million ≈ $84.35 Million |
+9.11% |
| 2019-09-30 | €66.12 Million ≈ $77.30 Million |
-11.20% |
| 2018-09-30 | €74.46 Million ≈ $87.06 Million |
+8.70% |
| 2017-09-30 | €68.50 Million ≈ $80.09 Million |
+44.18% |
| 2016-09-30 | €47.51 Million ≈ $55.55 Million |
+56.25% |
| 2015-09-30 | €30.41 Million ≈ $35.55 Million |
+21.28% |
| 2014-09-30 | €25.07 Million ≈ $29.31 Million |
-0.10% |
| 2013-09-30 | €25.10 Million ≈ $29.34 Million |
+27.33% |
| 2012-09-30 | €19.71 Million ≈ $23.04 Million |
-- |
About BRAIN Biotech AG
BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of re… Read more